Table 1.
Sample Characteristics
| Atazanavir Buprenorphine N=10 | Atazanavir Control N = 10 | Atazanavir/Ritonavir Buprenorphine N = 10 | Atazanavir/Ritonavir Control N = 10 | |
|---|---|---|---|---|
| Age (yrs) |
38 (2.7)* |
42 (3.1) |
37 (2.7) |
40 (3.1) |
| Weight (kg) |
83.4 (4.5) |
76.0 (4.4) |
87.6 (6.1) |
83.7 (4.9) |
| Buprenorphine/Naloxone Dose (mg/day) |
15.2 (0.8)/3.8 (0.2) |
N/A |
16.0 (0.0)/4.0 (0.0) |
N/A |
| Female |
3 |
4 |
4 |
3 |
| Race: | ||||
| African-American | 10 | 8 | 9 | 7 |
| Caucasian |
- |
2 |
1 |
3 |
| Substance Use Disorders: | ||||
| Opioid Dependence | 10 | - | 10 | - |
| Cocaine Abuse | 8 | 4 | 7 | 3 |
| Cannabis Abuse | 1 | 1 | 2 | 1 |
| Alcohol Abuse |
- |
1 |
1 |
1 |
| IDU |
1 |
0 |
2 |
0 |
| Nicotine Use (packs/day) |
0.6 (0.1) |
0.5 (0.2) |
0.7 (0.2) |
0.6 (0.2) |
| Hepatitis C Positive | 0 | 0 | 1 | 0 |
*
Mean (SE)